The global Wine Market was valued at USD 584.8 billion...
Read MoreThe global Cancer Diagnostics Market was valued at USD 30,424.8 million in 2025 and is projected to expand at a strong CAGR of 7.9% to reach approximately USD 65,079.2 million by 2036, driven by a rising global cancer burden, with the WHO’s International Agency for Research on Cancer projecting more than 35 million new cases in 2050, up 77% from 2022, expanding screening programmes, the shift toward precision oncology that requires genomic testing, and adoption of liquid biopsy, digital pathology, and AI-assisted imaging. The market encompasses cancer diagnostics by product, technology, test type, cancer type, application, and end user.
The Cancer Diagnostics Market’s strong 7.9% CAGR reflects growing need for earlier and more precise cancer detection. IARC estimates that there were about 20 million new cancer cases and 9.7 million cancer deaths in 2022, with lung, female breast, colorectal, prostate, and stomach cancers the most common. Ageing populations, lifestyle factors, and better detection are increasing case numbers, while new therapies that target specific mutations require more testing for each patient. Spending is shifting toward molecular testing and digital tools, which offer higher value per test and support personalized treatment decisions.
What does cancer diagnostics include?
Cancer diagnostics covers imaging such as CT, MRI, PET, mammography, and ultrasound; tissue biopsy and pathology; laboratory tests including tumor markers and immunohistochemistry; molecular and genomic tests such as PCR and next-generation sequencing; and liquid biopsy tests that analyse tumor DNA in blood. These tools are used for screening, diagnosis, staging, treatment selection, and monitoring. Diagnostics account for a relatively small share of cancer care costs but strongly influence treatment decisions. It spans imaging, tissue biopsy, laboratory tests, molecular assays, and digital pathology.
How large is the global cancer burden?
IARC estimates about 20 million new cancer cases in 2022, with lung cancer accounting for 12.4% of cases and 18.7% of deaths. New cases are projected to exceed 35 million by 2050, with the largest relative increases in low and medium Human Development Index countries. This growth will increase demand for diagnostic capacity worldwide. Breast cancer is the most common cancer among women and lung cancer the leading cause of cancer death.
Why is screening important?
Screening finds cancers at earlier stages, when treatment is more effective and less costly. Established programmes include mammography for breast cancer, colonoscopy and stool tests for colorectal cancer, cervical cytology and HPV testing, and low-dose CT for lung cancer in high-risk groups. Expanding eligibility and new tests increase screening volumes. Lung cancer screening with low-dose CT is being introduced in more countries.
What is precision oncology?
Many cancer therapies target specific genetic mutations or biomarkers, such as EGFR, ALK, HER2, BRCA, and PD-L1. Companion diagnostic tests identify which patients are likely to benefit. Next-generation sequencing panels test many genes at once, and guidelines increasingly recommend broad genomic profiling for advanced cancers. Testing rates for key biomarkers still vary widely between hospitals and countries. Biomarker testing identifies patients who are likely to benefit from targeted therapies.
How is liquid biopsy changing diagnostics?
Liquid biopsy detects tumor DNA, RNA, or cells in blood, allowing less invasive testing. It is used to identify mutations when tissue is insufficient, monitor treatment response, and detect minimal residual disease after surgery. Multi-cancer early detection tests are being studied for screening. Adoption depends on clinical evidence and reimbursement. Minimal residual disease testing helps doctors decide whether more treatment is needed after surgery. Blood-based tests can detect tumor DNA and monitor response to treatment.
What role does AI play?
AI tools help radiologists detect suspicious lesions on mammograms, CT scans, and other images, and help pathologists analyse digital slides. They can improve accuracy, reduce workload, and prioritize urgent cases. Regulatory approvals for AI-based diagnostic tools are increasing. Digital pathology also allows remote review and second opinions. AI tools help radiologists and pathologists read images faster and more consistently.
Which cancer types drive testing?
Breast, lung, colorectal, and prostate cancers account for the largest testing volumes because of their high incidence and established screening. Blood cancers rely heavily on flow cytometry and molecular testing. Rare cancers increasingly use genomic profiling. Hematology diagnostics use flow cytometry and molecular tests to classify blood cancers.
Who uses cancer diagnostics?
Hospitals, independent laboratories, diagnostic imaging centers, cancer research institutes, and physician offices are the main users. Reference laboratories perform complex molecular tests, while hospitals provide imaging and pathology. Pharmaceutical companies use diagnostics in clinical trials. Centralized laboratories handle complex genomic tests, while hospitals focus on routine work.
What challenges face the market?
Reimbursement for new tests, especially multi-cancer screening, is uncertain. Shortages of pathologists and radiologists limit capacity. Access to advanced diagnostics is limited in many low- and middle-income countries. Workforce shortages are especially severe in pathology.
Which cancer diagnostics market segments are growing fastest?
Liquid biopsy; next-generation sequencing; companion diagnostics; AI-enabled imaging and digital pathology; and lung and colorectal cancer screening are the fastest-growing segments. Colorectal screening with stool DNA tests has grown quickly in the United States.
Key Players: Roche Diagnostics, Abbott, Siemens Healthineers, GE HealthCare, Philips, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Danaher (Leica Biosystems), Exact Sciences, Guardant Health, GRAIL, Hologic, BD
The Cancer Diagnostics Market’s strong 7.9% CAGR from USD 30,424.8 million in 2025 toward approximately USD 65,079.2 million by 2036 is anchored in the rising cancer burden, expanding screening, precision oncology, and new technologies. Companies such as Roche Diagnostics, Illumina, and Siemens Healthineers are investing in molecular, imaging, and AI tools. Over the forecast period, liquid biopsy, genomic testing, and AI will drive strong growth. Expanding capacity in low- and middle-income countries will be essential as the global cancer burden grows. Diagnostic companies that combine molecular, imaging, and digital capabilities will be best placed.
Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.
The global Wine Market was valued at USD 584.8 billion...
Read MoreThe global Mattress Market was valued at USD 51.8 billion...
Read MoreThe global Floating Power Plant Market was valued at USD...
Read MoreWhatsApp us